MedTrace Logo

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-09-29

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

The interventions involved in this study are:

* Carboplatin
* Nivolumab

Conditions

Interventions

DRUG

Carboplatin

Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.

DRUG

Nivolumab

Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2021-09-28
Completion
2026-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414684 on ClinicalTrials.gov